Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model

  • Authors:
    • Xingqian Zhang
    • Wenhan Mei
    • Leilei Zhang
    • Hai Yu
    • Xiaoping Zhao
    • Xianqun Fan
    • Guanxiang Qian
    • Shengfang Ge
  • View Affiliations

  • Published online on: November 1, 2009     https://doi.org/10.3892/or_00000557
  • Pages: 1213-1220
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A strong CTL response is dependent upon a high level of expression of specific class I major histocompatibility complex (MHC)/peptide complexes at the cell surface. An epitope-linked β2-microglobulin (β2m) molecule could provide a simple and more efficient means to enhance the formation of defined MHC/peptide complexes. However, the ability of an epitope-linked β2m molecule to elicit primary CTL responses in vivo is still unknown. In this study, we modified the P1A tumor cell vaccine by addition of the tumor-associated epitope (TAE)-linked β2m molecule and co-stimulatory molecule CD80 to improve the efficiency in the application of the vaccine. A eukaryotic co-expression vector consisting of the P1A35-43-linked β2m molecule and the murine CD80 gene was constructed. P815 cell lines stably expressing P1A35-43-linked β2m molecule and/or CD80 were established after transfection, by selection under G418. Administration of these inactivated tumor cell vaccines allowed the TAE-specific CD8+ T cell responses to be examined in vivo. Our results indicate that immunization with P815 cells expressing both the P1A35-43-linked β2m molecule and the murine CD80 gene elicited a significantly stronger antitumor immune response than the single-modified tumor cell vaccines (expressing either P1A35-43-linked β2m or CD80 alone). These findings support the feasibility and effectiveness of developing a dual-modified tumor cell vaccine consisting of the epitope-linked β2m molecule and a co-stimulatory molecule.

Related Articles

Journal Cover

November 2009
Volume 22 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Mei W, Zhang L, Yu H, Zhao X, Fan X, Qian G and Ge S: Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model. Oncol Rep 22: 1213-1220, 2009
APA
Zhang, X., Mei, W., Zhang, L., Yu, H., Zhao, X., Fan, X. ... Ge, S. (2009). Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model. Oncology Reports, 22, 1213-1220. https://doi.org/10.3892/or_00000557
MLA
Zhang, X., Mei, W., Zhang, L., Yu, H., Zhao, X., Fan, X., Qian, G., Ge, S."Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model". Oncology Reports 22.5 (2009): 1213-1220.
Chicago
Zhang, X., Mei, W., Zhang, L., Yu, H., Zhao, X., Fan, X., Qian, G., Ge, S."Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model". Oncology Reports 22, no. 5 (2009): 1213-1220. https://doi.org/10.3892/or_00000557